SCHEMBL948117

SCHEMBL948117

Cc1nc(COC2CCN(C(=O)OC(C)(C)C)CC2)cn1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.49
PRMT5 O14744 2/20 0.43
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
CACNB4 O00305 1/20 0.43
CACNA1A O00555 1/20 0.43
CACNA1G O43497 1/20 0.43
CACNG3 O60359 1/20 0.43
CACNA1F O60840 1/20 0.43
CACNA1H O95180 1/20 0.43
CACNB3 P54284 1/20 0.43
CACNA2D1 P54289 1/20 0.43
CACNG7 P62955 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNA1D Q01668 1/20 0.43
CACNB1 Q02641 1/20 0.43
CACNG1 Q06432 1/20 0.43
CACNB2 Q08289 1/20 0.43
CACNA1S Q13698 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL948603 0.85 KDM4E (0.45) GPR119KDM4EPKMSTSMEN1
SCHEMBL14433203 0.82 GPR119 (0.46) GPR119PRMT5KDM4EPKMWDR77
SCHEMBL14433205 0.81 GPR119 (0.45) GPR119PRMT5KDM4EPKMWDR77
SCHEMBL950602 0.77 GPR119 (0.44) GPR119KDM4EPKMSTSMEN1
SCHEMBL950601 0.77 GPR119 (0.44) GPR119KDM4EPKMSTSMEN1
SCHEMBL3249107 0.77 STS (0.58) GPR119PRMT5KDM4EPKMWDR77
SCHEMBL8481341 0.76 GPR119 (0.52) GPR119PRMT5KDM4EPKMWDR77
SCHEMBL27111236 0.76 GPR119 (0.52) GPR119PRMT5KDM4EPKMWDR77
SCHEMBL27111240 0.75 GPR119 (0.53) GPR119PRMT5KDM4EPKMWDR77
SCHEMBL27111209 0.74 GPR119 (0.52) GPR119PRMT5KDM4EPKMWDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 GPR119 1327/4885PRMT5 217/4885KDM4E 1356/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 GPR119 1118/4885PRMT5 131/4885KDM4E 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.